A Conversation with the US FDA: Strategies to Advance the Use of Quality by Design and Implement ICH E6(R3) – Nov. 23, 2026
Session Description
November 23 2026 @ 11:00 am - 12:00 pm
Join us for an engaging conversation with the FDA as we explore practical and operational strategies for integrating Quality by Design (QbD) principles into clinical trial planning and execution. The keynote presentation will be delivered by David Burrow, Director, Office of Scientific Investigations and Office of Compliance, CDER FDA. The session will be moderated by Shila Rastegar, Health Canada Regulatory Operations and Enforcement (retired).
Learning Objectives:
- Apply Quality by Design (QbD)
- Translate ICH E6 (R3) into practice
- Identify and manage Critical-to-Quality factors
- Explore FDA/CDER tools and resources
